Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
376 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2014', provides an overview of the Amyotrophic Lateral Sclerosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Amyotrophic Lateral Sclerosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Amyotrophic Lateral Sclerosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 6 Amyotrophic Lateral Sclerosis Overview 7 Therapeutics Development 8 Amyotrophic Lateral Sclerosis - Therapeutics under Development by Companies 10 Amyotrophic Lateral Sclerosis - Therapeutics under Investigation by Universities/Institutes 17 Amyotrophic Lateral Sclerosis - Pipeline Products Glance 20 Amyotrophic Lateral Sclerosis - Products under Development by Companies 24 Amyotrophic Lateral Sclerosis - Products under Investigation by Universities/Institutes 31 Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development 35 Amyotrophic Lateral Sclerosis - Therapeutics Assessment 95 Drug Profiles 107 Amyotrophic Lateral Sclerosis - Recent Pipeline Updates 307 Amyotrophic Lateral Sclerosis - Dormant Projects 347 Amyotrophic Lateral Sclerosis - Discontinued Products 350 Amyotrophic Lateral Sclerosis - Product Development Milestones 351 Appendix 358
List of Tables Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2014 25 Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis, H2 2014 26 Number of Products under Development by Companies, H2 2014 28 Number of Products under Development by Companies, H2 2014 (Contd..1) 29 Number of Products under Development by Companies, H2 2014 (Contd..2) 30 Number of Products under Development by Companies, H2 2014 (Contd..3) 31 Number of Products under Development by Companies, H2 2014 (Contd..4) 32 Number of Products under Development by Companies, H2 2014 (Contd..5) 33 Number of Products under Investigation by Universities/Institutes, H2 2014 35 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 36 Comparative Analysis by Late Stage Development, H2 2014 37 Comparative Analysis by Clinical Stage Development, H2 2014 38 Comparative Analysis by Early Stage Development, H2 2014 39 Comparative Analysis by Unknown Stage Development, H2 2014 40 Products under Development by Companies, H2 2014 41 Products under Development by Companies, H2 2014 (Contd..1) 42 Products under Development by Companies, H2 2014 (Contd..2) 43 Products under Development by Companies, H2 2014 (Contd..3) 44 Products under Development by Companies, H2 2014 (Contd..4) 45 Products under Development by Companies, H2 2014 (Contd..5) 46 Products under Development by Companies, H2 2014 (Contd..6) 47 Products under Investigation by Universities/Institutes, H2 2014 48 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 49 Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 50 Products under Investigation by Universities/Institutes, H2 2014 (Contd..3) 51 Amyotrophic Lateral Sclerosis - Pipeline by AB Science, H2 2014 52 Amyotrophic Lateral Sclerosis - Pipeline by Aestus Therapeutics, Inc., H2 2014 53 Amyotrophic Lateral Sclerosis - Pipeline by AlzProtect SAS, H2 2014 54 Amyotrophic Lateral Sclerosis - Pipeline by Amorfix Life Sciences Ltd., H2 2014 55 Amyotrophic Lateral Sclerosis - Pipeline by Anavex Life Sciences Corp., H2 2014 56 Amyotrophic Lateral Sclerosis - Pipeline by Angion Biomedica Corp., H2 2014 57 Amyotrophic Lateral Sclerosis - Pipeline by Apodemus AB, H2 2014 58 Amyotrophic Lateral Sclerosis - Pipeline by BBB Therapeutics B.V., H2 2014 59 Amyotrophic Lateral Sclerosis - Pipeline by BioCrea GmbH, H2 2014 60 Amyotrophic Lateral Sclerosis - Pipeline by Biogen Idec Inc., H2 2014 61 Amyotrophic Lateral Sclerosis - Pipeline by Bionure Farma, S.L., H2 2014 62 Amyotrophic Lateral Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2014 63 Amyotrophic Lateral Sclerosis - Pipeline by CalAsia Pharmaceuticals, Inc., H2 2014 64 Amyotrophic Lateral Sclerosis - Pipeline by Calico LLC, H2 2014 65 Amyotrophic Lateral Sclerosis - Pipeline by Cellceutix Corporation, H2 2014 66 Amyotrophic Lateral Sclerosis - Pipeline by Cellular Biomedicine Group, Inc., H2 2014 67 Amyotrophic Lateral Sclerosis - Pipeline by Chronos Therapeutics Limited, H2 2014 68 Amyotrophic Lateral Sclerosis - Pipeline by Cytokinetics, Inc., H2 2014 69 Amyotrophic Lateral Sclerosis - Pipeline by D-Pharm Ltd., H2 2014 70 Amyotrophic Lateral Sclerosis - Pipeline by Daval International Ltd., H2 2014 71 Amyotrophic Lateral Sclerosis - Pipeline by Eisai Co., Ltd., H2 2014 72 Amyotrophic Lateral Sclerosis - Pipeline by Evotec AG, H2 2014 73 Amyotrophic Lateral Sclerosis - Pipeline by ExSAR Corporation, H2 2014 74 Amyotrophic Lateral Sclerosis - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2014 75 Amyotrophic Lateral Sclerosis - Pipeline by GlaxoSmithKline plc, H2 2014 76 Amyotrophic Lateral Sclerosis - Pipeline by Glialogix, Inc., H2 2014 77 Amyotrophic Lateral Sclerosis - Pipeline by Grifols, S.A., H2 2014 78 Amyotrophic Lateral Sclerosis - Pipeline by Herantis Pharma plc., H2 2014 79 Amyotrophic Lateral Sclerosis - Pipeline by ImStar Therapeutics Inc., H2 2014 80 Amyotrophic Lateral Sclerosis - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2014 81 Amyotrophic Lateral Sclerosis - Pipeline by Kadimastem Ltd., H2 2014 82 Amyotrophic Lateral Sclerosis - Pipeline by KineMed, Inc., H2 2014 83 Amyotrophic Lateral Sclerosis - Pipeline by Kringle Pharma, Inc., H2 2014 84 Amyotrophic Lateral Sclerosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2014 85 Amyotrophic Lateral Sclerosis - Pipeline by Lead Discovery Center GmbH, H2 2014 86 Amyotrophic Lateral Sclerosis - Pipeline by Maas Biolab, H2 2014 87 Amyotrophic Lateral Sclerosis - Pipeline by Mallinckrodt plc, H2 2014 88 Amyotrophic Lateral Sclerosis - Pipeline by miRagen Therapeutics, Inc., H2 2014 89 Amyotrophic Lateral Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 90 Amyotrophic Lateral Sclerosis - Pipeline by Neuralstem, Inc., H2 2014 91 Amyotrophic Lateral Sclerosis - Pipeline by Neuraltus Pharmaceuticals, Inc., H2 2014 92 Amyotrophic Lateral Sclerosis - Pipeline by Neurimmune Holding AG, H2 2014 93 Amyotrophic Lateral Sclerosis - Pipeline by Neurodyn Inc., H2 2014 94 Amyotrophic Lateral Sclerosis - Pipeline by Neurotec Pharma SL, H2 2014 95 Amyotrophic Lateral Sclerosis - Pipeline by Neurotune AG, H2 2014 96 Amyotrophic Lateral Sclerosis - Pipeline by Newron Pharmaceuticals S.p.A., H2 2014 97 Amyotrophic Lateral Sclerosis - Pipeline by Nexgenix Pharmaceuticals, LLC, H2 2014 98 Amyotrophic Lateral Sclerosis - Pipeline by Orphazyme ApS, H2 2014 99 Amyotrophic Lateral Sclerosis - Pipeline by Paladin Labs Inc., H2 2014 100 Amyotrophic Lateral Sclerosis - Pipeline by Pharnext SAS, H2 2014 101 Amyotrophic Lateral Sclerosis - Pipeline by Q Therapeutics, Inc., H2 2014 102 Amyotrophic Lateral Sclerosis - Pipeline by Regenesance BV, H2 2014 103 Amyotrophic Lateral Sclerosis - Pipeline by reMYND, H2 2014 104 Amyotrophic Lateral Sclerosis - Pipeline by RhinoCyte, Inc., H2 2014 105 Amyotrophic Lateral Sclerosis - Pipeline by RXi Pharmaceuticals Corporation, H2 2014 106 Amyotrophic Lateral Sclerosis - Pipeline by Saneron CCEL Therapeutics, Inc., H2 2014 107 Amyotrophic Lateral Sclerosis - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 108 Amyotrophic Lateral Sclerosis - Pipeline by Spherium biomed S.L., H2 2014 109 Amyotrophic Lateral Sclerosis - Pipeline by Varinel, Inc., H2 2014 110 Amyotrophic Lateral Sclerosis - Pipeline by ViroMed Co., Ltd., H2 2014 111 Assessment by Monotherapy Products, H2 2014 112 Assessment by Combination Products, H2 2014 113 Number of Products by Stage and Target, H2 2014 115 Number of Products by Stage and Mechanism of Action, H2 2014 118 Number of Products by Stage and Route of Administration, H2 2014 121 Number of Products by Stage and Molecule Type, H2 2014 123 Amyotrophic Lateral Sclerosis Therapeutics - Recent Pipeline Updates, H2 2014 324 Amyotrophic Lateral Sclerosis - Dormant Projects, H2 2014 364 Amyotrophic Lateral Sclerosis - Discontinued Products, H2 2014 367
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
